Results 21 to 30 of about 68,738 (313)
Journal of Translational Medicine, 2019 Background A hallmark of pancreatic ductal adenocarcinoma is the desmoplastic reaction, but its impact on the tumor behavior remains controversial.
Fabio Grizzi +18 more
doaj +1 more source
Surgical Treatment of Pancreatic Ductal Adenocarcinoma [PDF]
Cancers, 2021 Pancreatic ductal adenocarcinoma (PDAC) represents an aggressive tumor of the digestive system with still low five-year survival of less than 10%. Although there are improvements for multimodal therapy of PDAC, surgery still remains the effective way to treat the disease.
Kongyuan Wei, Thilo Hackert
openaire +5 more sources
Familial Pancreatic Ductal Adenocarcinoma [PDF]
The American Journal of Pathology, 2019 Pancreatic ductal adenocarcinoma (PDAC), although a rare disease, has a poor prognosis. With 5-year overall survival of 8%, there is a critical need to detect PDAC early or at a premalignant stage. Current screening methods are largely imaging based, but a more focused screening approach based on modifiable and nonmodifiable risk factors may improve ...
Kelly E. Diaz, Aimee L. Lucas
openaire +3 more sources
Immune response and drug therapy based on ac4C-modified gene in pancreatic cancer typing
Frontiers in Immunology, 2023 N-4 cytidine acetylation (ac4C) is an epitranscriptome modification catalyzed by N-acetyltransferase 10 (NAT10) and is essential for cellular mRNA stability, rRNA biosynthesis, cell proliferation, and epithelial-mesenchymal transition (EMT).
Dong Xu +5 more
doaj +1 more source
Deciphering CHFR Role in Pancreatic Ductal Adenocarcinoma [PDF]
Frontiers in Medicine, 2021 Checkpoint with forkhead-associated and ring finger domains (CHFR) has been proposed as a predictive and prognosis biomarker for different tumor types, but its role in pancreatic ductal adenocarcinoma (PDAC) remains unknown. The aim of this study was two-pronged: to review the role of CHFR in PDAC and evaluating CHFR as a potential predictive biomarker
Iranzu González-Borja +32 more
openaire +10 more sources
Biomarkers in pancreatic ductal adenocarcinoma
Clinical and Translational Oncology, 2017 Pancreatic ductal adenocarcinoma (PDAC) is currently the third most frequent form of malignancy. The role of biomarkers in the diagnostic and therapeutic strategy of cancer is constantly expanding. Translational research is already changing paradigms in tumours encompassing from early diagnosis to precision medicine in advanced disease.
J. Gallego +4 more
openaire +4 more sources
Tumor Biology, 2020 Pancreatic ductal adenocarcinoma is the most common and aggressive type of pancreatic cancer, with a 5-year survival rate that is less than 10%. New biomarkers to aid in predicting the prognosis of pancreatic ductal adenocarcinoma patients are needed ...
Matilda Holm +5 more
doaj +1 more source
Photodynamic Therapy for Pancreatic Ductal Adenocarcinoma [PDF]
Cancers, 2021 Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal of human cancers. Clinical trials of various chemotherapy, radiotherapy, targeted agents and combination strategies have generally failed to provide meaningful improvement in survival for patients with unresectable disease.
Vida Karimnia +2 more
openaire +2 more sources
Advances in the management of pancreatic ductal adenocarcinoma [PDF]
Canadian Medical Association Journal, 2021 KEY POINTS The incidence of pancreatic ductal adenocarcinoma (PDAC) is rising and PDAC is projected to become the third leading cause of cancer death in Canada.[1][1] Although risk factors for PDAC are known, the reason for its rising incidence is not.
Steven Gallinger +2 more
openaire +3 more sources
How fibrosis influences imaging and surgical decisions in pancreatic cancer
Frontiers in Physiology, 2012 Our understanding of pancreatic ductal adenocarcinoma is shifting away from a disease of malignant ductal cells-only, towards a complex system where tumor evolution is a result of interaction of cancer cells with their microenvironment.
Mert eErkan +7 more
doaj +1 more source